Viracta Therapeutics, Inc. (VIRX)
NASDAQ: VIRX · IEX Real-Time Price · USD
0.880
-0.029 (-3.19%)
Apr 19, 2024, 2:35 PM EDT - Market open
Viracta Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for VIRX stock have an average target of 7.60, with a low estimate of 4.00 and a high estimate of 13. The average target predicts an increase of 763.64% from the current stock price of 0.88.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for VIRX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Maintains $13 | Buy | Maintains | $13 | +1,377.27% | Apr 17, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +354.55% | Apr 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $4 | Strong Buy | Reiterates | $4 | +354.55% | Mar 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $4 | Strong Buy | Maintains | $10 → $4 | +354.55% | Jan 5, 2024 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $6 | Buy | Maintains | $7 → $6 | +581.82% | Nov 10, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
3.57M
EPS This Year
-1.34
from -1.32
EPS Next Year
-1.24
from -1.34
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 7.4M | 47.0M | 306.9M | 129.6M |
| Avg | n/a | 3.6M | 30.9M | 178.0M | 125.9M |
| Low | n/a | n/a | 15.6M | 55.6M | 120.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 1,216.0% | 892.2% | -27.2% |
| Avg | - | - | 766.3% | 475.5% | -29.3% |
| Low | - | - | 336.5% | 79.9% | -32.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.21 | -1.14 | -1.05 | 3.41 | -0.03 |
| Avg | -1.34 | -1.24 | -1.29 | 1.32 | -0.03 |
| Low | -1.39 | -1.31 | -1.49 | -0.66 | -0.03 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.